{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:02:41Z","timestamp":1791050561999,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.clinre.2011.03.009","type":"journal-article","created":{"date-parts":[[2011,5,6]],"date-time":"2011-05-06T12:59:59Z","timestamp":1304686799000},"page":"521-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapy for hepatic fibrosis: Revisiting the preclinical models"],"prefix":"10.1016","volume":"35","author":[{"given":"D. Montgomery","family":"Bissell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2011.03.009_bib0005","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21459","article-title":"Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference","volume":"45","author":"Friedman","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2011.03.009_bib0010","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1073\/pnas.82.24.8681","article-title":"Hepatic lipocytes: the principal collagen-producing cells of normal rat liver","volume":"82","author":"Friedman","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2011.03.009_bib0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0014-4827(82)90283-X","article-title":"Fat-storing cells of the rat liver. Their isolation and purification","volume":"139","author":"Knook","year":"1982","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.clinre.2011.03.009_bib0020","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cld.2008.07.011","article-title":"Current and future anti-fibrotic therapies for chronic liver disease","volume":"12","author":"Rockey","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinre.2011.03.009_bib0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.gcb.2009.07.021","article-title":"Rationale and targets for antifibrotic therapies","volume":"33","author":"Schuppan","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.clinre.2011.03.009_bib0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/hep.1840100508","article-title":"Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis","volume":"10","author":"Czaja","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2011.03.009_bib0035","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.1840160325","article-title":"Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma","volume":"16","author":"Rockey","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2011.03.009_bib0040","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJM199910213411703","article-title":"A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis","volume":"341","author":"Ziesche","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2011.03.009_bib0045","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/archderm.1990.01670340047006","article-title":"A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings","volume":"126","author":"Granstein","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clinre.2011.03.009_bib0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.21561","article-title":"Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis","volume":"45","author":"Pockros","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2011.03.009_bib0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2011.03.009_bib0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2958","article-title":"Strategies for treating idiopathic pulmonary fibrosis","volume":"9","author":"du Bois","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinre.2011.03.009_bib0065","first-page":"506","article-title":"Effects on the liver of chemicals encountered in the workplace","volume":"137","author":"Pond","year":"1982","journal-title":"West J Med"},{"key":"10.1016\/j.clinre.2011.03.009_bib0070","doi-asserted-by":"crossref","first-page":"10663","DOI":"10.1073\/pnas.94.20.10663","article-title":"Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma","volume":"94","author":"Shi","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2011.03.009_bib0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0030-1255350","article-title":"Inflammation and hepatic fibrosis","volume":"30","author":"Bissell","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clinre.2011.03.009_bib0080","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1172\/JCI41732","article-title":"Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice","volume":"120","author":"Berres","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinre.2011.03.009_bib0085","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinre.2011.03.009_bib0090","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","article-title":"Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression","volume":"135","author":"Patsenker","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2011.03.009_bib0095","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.21849","article-title":"Role of alphavbeta6 integrin in acute biliary fibrosis","volume":"46","author":"Wang","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2011.03.009_bib0100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0030-1255355","article-title":"Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease","volume":"30","author":"Rosmorduc","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clinre.2011.03.009_bib0105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1053\/jhep.2001.28457","article-title":"Transforming growth factor beta and the liver","volume":"34","author":"Bissell","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2011.03.009_bib0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2006.tb00292.x","article-title":"Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets","volume":"10","author":"Gressner","year":"2006","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clinre.2011.03.009_bib0115","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1242\/dev.124.13.2659","article-title":"TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes","volume":"124","author":"Sanford","year":"1997","journal-title":"Development"},{"key":"10.1016\/j.clinre.2011.03.009_bib0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/359693a0","article-title":"Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease","volume":"359","author":"Shull","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2011.03.009_bib0125","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/sj.onc.1208685","article-title":"Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-MSP- and HGF-mediated signaling networks","volume":"24","author":"Cheng","year":"2005","journal-title":"Oncogene"},{"issue":"Spec No. 1","key":"10.1016\/j.clinre.2011.03.009_bib0130","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1093\/hmg\/ddl486","article-title":"TGF-beta signaling alterations and susceptibility to colorectal cancer","volume":"16","author":"Xu","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clinre.2011.03.009_bib0135","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/dmd.106.013490","article-title":"Chemical modification of interleukin-10 with mannose 6-phosphate groups yields a liver-selective cytokine","volume":"35","author":"Rachmawati","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinre.2011.03.009_bib0140","doi-asserted-by":"crossref","first-page":"12719","DOI":"10.1073\/pnas.96.22.12719","article-title":"In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis","volume":"96","author":"George","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2011.03.009_bib0145","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1073\/pnas.96.5.2345","article-title":"Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat","volume":"96","author":"Qi","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2011.03.009_bib0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","article-title":"The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis","volume":"96","author":"Munger","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.clinre.2011.03.009_bib0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jhep.2004.10.025","article-title":"Adaptative bile duct proliferative response in experimental bile duct ischemia","volume":"42","author":"Beaussier","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2011.03.009_bib0160","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0030-1255354","article-title":"Macrophages: master regulators of inflammation and fibrosis","volume":"30","author":"Wynn","year":"2010","journal-title":"Semin Liver Dis"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740111001100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740111001100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:47Z","timestamp":1761894707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740111001100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":32,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S2210740111001100"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2011.03.009","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy for hepatic fibrosis: Revisiting the preclinical models","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2011.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}